EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Intensive treatment in order to minimize the Ph-positive clone in CML



Intensive treatment in order to minimize the Ph-positive clone in CML



Bone Marrow Transplantation 17(SUPPL 3): S63-S64



With the rationale that a significant reduction of the malignant clone in CML might prolong time to metamorphosis, intensive treatment was given to patients ltoreq 55 years. Six months of hydroxyurea and high dose interferon-alpha (IFN-alpha) was followed by one to three courses of intensive chemotherapy. Patients who had a donor were allotransplanted and patients who became Ph-negative in bone marrow were autotransplanted. On 1 May 1995, 160 patients were registered in the study. Fifty-one percent of the patients who received six months IFN-alpha and hydroxyurea had a significant Ph-reduction and 5% became Ph-negative. The corresponding figures after two intensive chemotherapy courses were 47 and 28%, respectively. Twenty-seven of 30 autotransplanted patients have been analysed for Ph. Seventeen have relapsed cytogenetically, while ten are Ph-negative 1-64 + months after ABMT. BMT was performed in 59 patients. The actuarial 6-year survival from diagnosis of all 160 registered patients is 68%, which seems to be better than for age-matched historical controls.

(PDF emailed within 1 workday: $29.90)

Accession: 008890003

Download citation: RISBibTeXText

PMID: 8769705



Related references

Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Leukemia & Lymphoma 7 Suppl: 55-57, 1992

Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Stem Cells 11 Suppl 3: 73-76, 1993

Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Swedish CML-group. Bone Marrow Transplantation 14 Suppl 3: S55-S56, 1994

Intensive treatment to reduce the Ph-positive clone in chronic myelogenic leukemia. Blood 82(10 SUPPL 1): 330A, 1993

Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia. Japanese Journal of Clinical Hematology 47(2): 111-114, 2006

Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). American Journal of Hematology 77(4): 420-420, 2004

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients. Clinical Advances in Hematology & Oncology 14(11): 892-894, 2016

Total care (spirituality, positive psychology, and surgical home) to minimize demoralization syndrome in intensive care unit setting. Southern Medical Journal 107(1): 58-58, 2014

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is not necessary, at least in induction. Clinical Advances in Hematology & Oncology 14(11): 892-896, 2016

Myelodysplastic syndrome supervening previously untreated chronic B-cell leukemia Demonstration of concomitant presence of a CD19+/immunoglobulin -rearrangement positive B-cell clone and a CD34+/AML1-ETO positive blast cell clone. Blood 86(10 SUPPL 1): 798A, 1995

Outbreak of a South West Pacific clone Panton-Valentine leucocidin-positive meticillin-resistant Staphylococcus aureus infection in a UK neonatal intensive care unit. Journal of Hospital Infection 80(4): 293-298, 2012

Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment. Japanese Journal of Clinical Hematology 55(6): 687-691, 2014

Evolution of a CD3-positive CD4-positive alpha/beta-T cell receptor-positive mature T cell clone from CD3-negative CD7-positive human bone marrow cells. Immunobiology 186(1-2): 107, 1992

Fetal thymic stromal cell clone induces deletion of double positive cd4 positive cd8 positive thymocytes. Immunobiology 181(2-3): 137, 1990